Abstract
Novel treatments that improve outcomes for patients with recurrent or metastatic endometrial cancer (EC) remain an unmet need. Aberrant signaling by fibroblast growth factors (FGFs) and FGF receptors (FGFRs) has been implicated in several human cancers. Activating mutations in FGFR2 have been found in up to 16% of ECs, suggesting an opportunity for targeted therapy. This review summarizes the role of the FGF pathway in angiogenesis and EC, and provides an overview of FGFR-targeted therapies under clinical development for the treatment of EC.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 37-47 |
| Number of pages | 11 |
| Journal | Current Problems in Cancer |
| Volume | 41 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 1 2017 |
Bibliographical note
Publisher Copyright:© 2017 The Authors
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Angiogenesis
- Endometrial cancer
- Fibroblast growth factor
Fingerprint
Dive into the research topics of 'Targeting fibroblast growth factor pathways in endometrial cancer'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS